CSL (ASX: CSL), an Australia-based global biotechnology company, announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for its HEMGENIX (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy intended to treat appropriate adults with haemophilia B.
The product is approved for the treatment of adults with haemophilia B who presently use factor IX prophylaxis therapy, or have present or historical life-threatening haemorrhage or have repeated, serious spontaneous bleeding episodes. The company said that during the ongoing clinical trial, the product decreased the rate of annual bleeds and 94% of the subjects discontinued factor IX prophylaxis and remained prophylaxis-free.
The approval is supported by outcomes from the ongoing HOPE-B trial. Outcomes from the study revealed that the product enabled patients to produce mean factor IX activity of 39% at six months and 36.7% at 24 months post infusion.
uniQure (Nasdaq: QURE) headed the multi-year clinical development program for HEMGENIX and sponsorship of the clinical trials moved to CSL subsequent to the acquisition of the global rights to commercialise the treatment.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial